<DOC>
	<DOCNO>NCT02727387</DOCNO>
	<brief_summary>Study treatment metastatic Ewing sarcoma high dos chemotherapy , radiotherapy maintenance therapy .</brief_summary>
	<brief_title>Protocol Treatment Metastatic Ewing Sarcoma</brief_title>
	<detailed_description>Study treatment Ewing metastatic sarcoma induction phase Vincristine ( VIN ) , Adriamycin ( ADM ) , Ciclofosfamide ( CYC ) , Ifosfamide ( IFO ) , Etoposide ( ETO ) radiotherapy ( RT ) follow consolidation phase Busulfan Melfalan ( BUMEL ) Peripheral Blood Stem Cells Transplantation ( PBSCT ) subsequent maintenance phase Ciclofosfamide Celecoxib High Risk ( HR ) patient . Very High Risk ( VHR ) patient receive prior frontline therapy Temozolomide Irinotecan ( TEMIRI ) , patient lung metastasis undergo total lung irradiation PBSCT</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically proven Ewing 's sarcoma Age â‰¤ 40 year No previous treatment Multiple skeletal metastasis bone marrow infiltration , with/without lung/pleural metastasis Signed Informed Consent Localized Ewing 's sarcoma Any contraindication study treatment Female patient accept use effective birth control method . Pregnant breastfeeding patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>